EGFR GENE MUTATION
Clinical trials for EGFR GENE MUTATION explained in plain language.
Never miss a new study
Get alerted when new EGFR GENE MUTATION trials appear
Sign up with your email to follow new studies for EGFR GENE MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail shows promise for Hard-to-Treat lung cancer
Disease control CompletedThis phase 2 trial tested a combination of chemotherapy (carboplatin or cisplatin plus pemetrexed) and immunotherapy (atezolizumab, with or without bevacizumab) in 150 people with advanced non-squamous non-small cell lung cancer that has EGFR, ALK, or ROS1 mutations and has progr…
Matched conditions: EGFR GENE MUTATION
Phase: PHASE2 • Sponsor: Centre Francois Baclesse • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New combo therapy shows promise against tough cancers
Disease control CompletedThis study tested a combination of two drugs—sEphB4-HSA and pembrolizumab—in 42 people with advanced non-small cell lung cancer or head & neck cancer that had spread or returned. The goal was to see if the combo could shrink tumors better than standard treatments. Participants ha…
Matched conditions: EGFR GENE MUTATION
Phase: PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New pill shows promise against lung cancer brain metastases
Disease control CompletedThis study tested a new drug called AZD3759 against standard targeted therapies (erlotinib or gefitinib) in 492 people with advanced EGFR-mutant lung cancer that had spread to the brain. The goal was to see if AZD3759, which is designed to better reach the brain, could keep the c…
Matched conditions: EGFR GENE MUTATION
Phase: PHASE2, PHASE3 • Sponsor: Alpha Biopharma (Jiangsu) Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 16:13 UTC